Citlali Ekaterina Rodriguez-Perez

Dr. Citlali Ekaterina Rodriguez-Perez


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VCVICTORIA CAMPOS-PEÑA
VICTORIA CAMPOS-PEÑA
PPPavel Salvador Pichardo-Rojas
Pavel Salvador Pichardo-Rojas
TSTalía Sánchez-Barbosa
Talía Sánchez-Barbosa
EOEmma Elisa Ortiz
Emma Elisa Ortiz
CRCitlali Ekaterina Rodriguez-Perez
Citlali Ekaterina Rodriguez-Perez
Danira Toral-RiosDanira Toral-Rios
Danira Toral-Rios
The presence of insoluble aggregates of amyloid β (Aβ) in the form of neuritic plaques (NPs) is one of the main features that define Alzheimer’s disease. Studies have suggested that the accumulation of these peptides in the brain significantly contributes to extensive neuronal loss. Furthermore, the content and distribution of cholesterol in the membrane have been shown to have an important effect on the production and subsequent accumulation of Aβ peptides in the plasma membrane, contributing to dysfunction and neuronal death. The monomeric forms of these membrane-bound peptides undergo several conformational changes, ranging from oligomeric forms to beta-sheet structures, each presenting different levels of toxicity. Aβ peptides can be internalized by particular receptors and trigger changes from Tau phosphorylation to alterations in cognitive function, through dysfunction of the cholinergic system. The goal of this review is to summarize the current knowledge on the role of lipids in Alzheimer’s disease and their relationship with the basal cholinergic system, as well as potential disease-modifying therapies.

Verified
Journal Article
Open access
PDF file
ALAdolfo López-Ornelas
Adolfo López-Ornelas
AJAdriana Jiménez
Adriana Jiménez
Gilberto Pérez--SánchezGilberto Pérez--Sánchez
Gilberto Pérez--Sánchez
CRCitlali Ekaterina Rodriguez-Perez
Citlali Ekaterina Rodriguez-Perez
ACAlejandro Corzo-Cruz
Alejandro Corzo-Cruz
EEEnrique Estudillo
Enrique Estudillo
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and its prevalence is increasing. Nowadays, very few drugs effectively reduce AD symptoms and thus, a better understanding of its pathophysiology is vital to design new effective schemes. Presymptomatic neuronal damage caused by the accumulation of Amyloid β peptide and Tau protein abnormalities remains a challenge, despite recent efforts in drug development. Importantly, therapeutic targets, biomarkers, and diagnostic techniques have emerged to detect and treat AD. Of note, the compromised blood-brain barrier (BBB) and peripheral inflammation in AD are becoming more evident, being harmful factors that contribute to the development of the disease. Perspectives from different pre-clinical and clinical studies link peripheral inflammation with the onset and progression of AD. This review aims to analyze the main factors and the contribution of impaired BBB in AD development. Additionally, we describe the potential therapeutic strategies using stem cells for AD treatment.

17 January 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EOEmma Elisa Ortiz
Emma Elisa Ortiz
PMPedro Montes
Pedro Montes
CRCitlali Ekaterina Rodriguez-Perez
Citlali Ekaterina Rodriguez-Perez
ERElizabeth Ruiz
Elizabeth Ruiz
TBTalía Sánchez Barbosa
Talía Sánchez Barbosa
VCVICTORIA CAMPOS-PEÑA
VICTORIA CAMPOS-PEÑA
Alzheimer’s disease (AD) represents an escalating global health crisis, constituting the leading cause of dementia among the elderly and profoundly impairing their quality of life. Current FDA-approved drugs, such as rivastigmine, donepezil, galantamine, and memantine, offer only modest symptomatic relief and are frequently associated with significant adverse effects. Faced with this challenge and in line with advances in the understanding of the pathophysiology of this neurodegenerative condition, various innovative therapeutic strategies have been explored. Here, we review novel approaches inspired by advanced knowledge of the underlying pathophysiological mechanisms of the disease. Among the therapeutic alternatives, immunotherapy stands out, employing monoclonal antibodies to specifically target and eliminate toxic proteins implicated in AD. Additionally, the use of medicinal plants is examined, as their synergistic effects among components may confer neuroprotective properties. The modulation of the gut microbiota is also addressed as a peripheral strategy that could influence neuroinflammatory and degenerative processes in the brain. Furthermore, the therapeutic potential of emerging approaches, such as the use of microRNAs to regulate key cellular processes and nanotherapy, which enables precise drug delivery to the central nervous system, is analyzed. Despite promising advances in these strategies, the incidence of Alzheimer’s disease continues to rise. Therefore, it is proposed that achieving effective treatment in the future may require the integration of combined approaches, maximizing the synergistic effects of different therapeutic interventions.

29 August 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EOEmma Elisa Ortiz
Emma Elisa Ortiz
MRMaria Elena Manriquez Ramirez
Maria Elena Manriquez Ramirez
PMPedro Montes
Pedro Montes
CRCitlali Ekaterina Rodriguez-Perez
Citlali Ekaterina Rodriguez-Perez
ERElizabeth Ruiz
Elizabeth Ruiz
VCVICTORIA CAMPOS-PEÑA
VICTORIA CAMPOS-PEÑA
Despite aggressive current therapies against glioblastoma (GB), residual tumor cells may remain at the edge of the surgical cavity after resection. These cells can rapidly proliferate, giving rise to tumor recurrence in more aggressive and drug-resistant forms. As photodynamic therapy (PDT) has advanced, it has emerged as an option to treat this brain tumor. The oncological basis of PDT involves the selective accumulation of a photosensitizer (PS) in the tumor, followed by its activation with electromagnetic radiation to generate reactive oxygen species (ROS), which induce tumor cell death. Given that first- and second-generation PSs present significant limitations, including poor tumor selectivity, suboptimal biodistribution, limited absorption within the therapeutic window, and slow systemic clearance, research has progressed toward the development of third-generation PSs based on nanotechnology to optimize their therapeutic properties. This review addresses the types of tumor cell death induced by PDT, as well as the advancements of PS design, focusing on titanium dioxide (TiO2) and zinc oxide (ZnO) nanoparticles. These nanomaterials can be designed as carriers, encapsulating or conjugating conventional PSs, or act as PSs themselves, due to their favorable biocompatibility and intrinsic photoreactivity. Additionally, they can be functionalized with targeting ligands to achieve tumor-specific delivery, enhancing therapeutic selectivity while minimizing toxicity to healthy tissue. Overall, these nanotechnology-based PSs represent a versatile and promising therapeutic paradigm that warrants further investigation through basic research, supporting the development and potential clinical translation of a more precise and effective PDT-based intervention for glioblastoma, initially aimed at eliminating intra-surgical post-resection residual tumor cells.

29 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PMPedro Montes
Pedro Montes
EOEmma Elisa Ortiz
Emma Elisa Ortiz
CRCitlali Ekaterina Rodriguez-Perez
Citlali Ekaterina Rodriguez-Perez
ERElizabeth Ruiz
Elizabeth Ruiz
DSDaniela Silva-Adaya
Daniela Silva-Adaya
VCVICTORIA CAMPOS-PEÑA
VICTORIA CAMPOS-PEÑA
Progesterone (P4) is a neuroactive hormone having pleiotropic effects, supporting its pharmacological potential to treat global (cardiac-arrest-related) cerebral ischemia, a condition associated with an elevated risk of dementia. This review examines the current biochemical, morphological, and functional evidence showing the neuroprotective/neurorestorative effects of P4 against global cerebral ischemia (GCI). Experimental findings show that P4 may counteract pathophysiological mechanisms and/or regulate endogenous mechanisms of plasticity induced by GCI. According to this, P4 treatment consistently improves the performance of cognitive functions, such as learning and memory, impaired by GCI. This functional recovery is related to the significant morphological preservation of brain structures vulnerable to ischemia when the hormone is administered before and/or after a moderate ischemic episode; and with long-term adaptive plastic restoration processes of altered brain morphology when treatment is given after an episode of severe ischemia. The insights presented here may be a guide for future basic research, including the study of P4 administration schemes that focus on promoting its post-ischemia neurorestorative effect. Furthermore, considering that functional recovery is a desired endpoint of pharmacological strategies in the clinic, they could support the study of P4 treatment for decreasing dementia in patients who have suffered an episode of GCI.

19 August 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CRCitlali Ekaterina Rodriguez-Perez
Citlali Ekaterina Rodriguez-Perez
SRSonia Rodríguez-García
Sonia Rodríguez-García
MRMaria Elena Manriquez Ramirez
Maria Elena Manriquez Ramirez
AOA. Martin Ortiz-Torres
A. Martin Ortiz-Torres
FTF. Tzompantzi
F. Tzompantzi
EOEmma Elisa Ortiz
Emma Elisa Ortiz
Background/Objectives: This study reports the synthesis of TiO2 nanoparticles, their functionalization with folic acid (FA), and the subsequent loading with zinc phthalocyanine (ZnPc) to develop photosensitizers for photodynamic therapy (PDT) targeting glioma cells. Methods: TiO2, TiO2-FA, and TiO2-FA-ZnPc nanoparticles were synthesized via a sol–gel process involving the hydrolysis and condensation of titanium (IV) isopropoxide. FA and ZnPc were incorporated in vitro during the synthesis. The resulting materials were characterized by transmission and scanning electron microscopy (TEM and SEM), X-ray diffraction (XRD), Raman and UV–Vis spectroscopy, thermogravimetric analysis (TGA), and nitrogen adsorption–desorption measurements. Reactive oxygen species (ROS) generation was evaluated in vitro using the 1,3-diphenylisobenzofuran (DPBF) probe. A 40 ppm solution of each TiO2 system was irradiated with UV light, and the degradation of DPBF was monitored. Biological assays were conducted to assess the viability of human glioblastoma cells (LN18 and U251) incubated with the TiO2-based materials, with and without UV exposure. Human fibroblast cells (BJ) were used to evaluate biocompatibility. Results: All TiO2-based materials retained key characteristics, including high surface area (~600–700 m2/g), mesoporous structure (pore diameter ~4–5 nm), mixed anatase–amorphous morphology, and a bandgap of approximately 3.46 eV. The UV–Vis spectrum of TiO2-FA-ZnPc displayed additional absorption bands in the visible region (600–700 nm), consistent with ZnPc incorporation. Upon UV irradiation, the DPBF absorbance at 410 nm decreased over time, indicating ROS generation and resulting in complete degradation within 10 min (TiO2), 12 min (TiO2-FA), and 14 min (TiO2-FA-ZnPc). BJ cells exhibited good biocompatibility at all concentrations. LN18 and U251 cells showed no cytotoxicity below 100 μg/mL unless exposed to UV light. Conclusions: The synthesized TiO2-based systems demonstrate good biocompatibility and significant phototoxicity under UV irradiation, highlighting their strong potential for application in photodynamic therapy.